Lucid Diagnostics INC Form 4 insider transactions

Lucid Diagnostics Inc. reports a significant stock purchase by Director Dennis Matheis, acquiring 245,000 shares.

Lucid Diagnostics CEO Lishan Aklog received a grant of 2.17 million restricted common stock shares, vesting in 2029.

Lucid Diagnostics director Dennis Matheis was granted 123,000 shares of restricted common stock, vesting in May 2029.

Lucid Diagnostics Inc. director Debra White was granted 123,000 shares of common stock, vesting in 2029, under the company's 2018 Equity Plan.

Lucid Diagnostics Inc. director Ronald M. Sparks was granted 123,000 restricted common shares vesting in 2029.

Lucid Diagnostics Inc. Director Jacque J. Sokolov was granted 123,000 shares of restricted common stock, vesting in May 2029.

Lucid Diagnostics Director John R. Palumbo received a grant of 123,000 restricted shares, vesting in 2029.

Lucid Diagnostics Inc. Director Stanley Lapidus was granted 123,000 restricted common shares, vesting in 2029, under a pre-planned equity award.

Lucid Diagnostics Inc. director James L. Cox was granted 123,000 shares of restricted common stock, vesting in 2029.

Lucid Diagnostics Inc.'s Chief Financial Officer, Dennis M. McGrath, was granted 470,000 shares of restricted common stock with a vesting date in May 2029.

Lucid Diagnostics Inc.'s President and COO, Shaun O'Neil, was granted 620,000 shares of restricted common stock under the company's 2018 Equity Plan.

Lucid Diagnostics Inc. granted 300,000 restricted common stock shares to General Counsel and Secretary Michael Adam Gordon, vesting in 2029.

Lucid Diagnostics Director John R. Palumbo was granted 215,000 employee stock options with an exercise price of $1.03, vesting over approximately two years.

Lucid Diagnostics Director Dennis Matheis acquired 100,000 shares of common stock at an average price of $1.0184, increasing his direct beneficial ownership to 665,443 shares.

Lucid Diagnostics Inc. Director Dennis Matheis filed an amended Form 4, correcting his reported beneficial ownership to reflect a significantly larger stake in the company following recent stock acquisitions.

Director Matheis Dennis increased his holdings in Lucid Diagnostics through a series of purchases between May 20th and May 22nd, 2025.

Shaun O'Neil, President and COO of Lucid Diagnostics Inc., reports acquiring 300,000 shares of common stock on February 20, 2025, as part of a restricted stock grant.

Lucid Diagnostics CEO Aklog Lishan reports acquiring 300,000 shares of common stock and discloses beneficial ownership of 1,466,627 shares.

Director Jacque J. Sokolov acquired 112,800 shares of Lucid Diagnostics restricted stock on February 20, 2025, under the Issuer's 2018 Equity Plan.

Director Stanley Lapidus acquired 112,800 shares of Lucid Diagnostics Inc. restricted stock on February 20, 2025, under the company's 2018 Equity Plan.

Director Dennis Matheis acquires 112,800 shares of restricted stock in Lucid Diagnostics, while disposing of 0 shares.

Director James L. Cox of Lucid Diagnostics Inc. reports the acquisition of 112,800 shares of restricted stock with a vesting date in 2028.

Lucid Diagnostics' Chief Financial Officer, Dennis McGrath, reports acquiring 300,000 shares of common stock through a restricted stock grant.

Michael Adam Gordon, General Counsel and Secretary of Lucid Diagnostics Inc., acquired 300,000 shares of common stock on February 20, 2025, and disposed of 700,000 shares.

Director Debra White acquired 112,800 shares of Lucid Diagnostics common stock on February 20, 2025, as part of a restricted stock grant.

Director Ronald M. Sparks acquired 112,800 shares of Lucid Diagnostics Inc. common stock on February 20, 2025, as part of a restricted stock grant.

Director Dennis Matheis acquired employee stock options in Lucid Diagnostics Inc. on May 8, 2024.

Michael Adam Gordon, General Counsel and Secretary of Lucid Diagnostics Inc., acquired 400,000 shares of restricted stock on May 7, 2024, under the company's 2018 Equity Plan.

Shaun O'Neil, President and COO of Lucid Diagnostics Inc., received a grant of 400,000 restricted shares of common stock.

Lucid Diagnostics' Chief Financial Officer, Dennis M. McGrath, acquired 400,000 shares of restricted stock on May 7, 2024, under the company's 2018 Equity Plan.